GSK to buy US cancer drug firm IDRx for up to $1.15bn | GlaxoSmithKline
skylinenews GSK has struck a deal worth up to $1.15bn (£950m) to acquire a Massachusetts-based developer of rare cancer therapies, in…
Read MoreGlaxoSmithKline
GSK has struck a deal worth up to $1.15bn (£950m) to acquire a Massachusetts-based developer of rare cancer therapies, in…
Read More